Inhibrx Biosciences, Inc.
A clinical-stage biopharmaceutical company engineering biologic therapies for cancer. Its lead candidate, ozekibart, cut the risk of disease progression or death in a late-stage trial for chondrosarcoma, a rare bone cancer, and it is also studying INBRX-106 with the immunotherapy Keytruda. The name blends "inhibit" and "Rx" (prescription), and the company took its present form in 2024 when Sanofi bought one of its programs, spinning out the rest.
Granted 818.6K · Bought 451.5K
Granted 761.4K · Bought 164.0K
Granted 513.9K
Granted 149.6K · Bought 75.0K
Sold 350.0K
Bought 20.4K
Bought 10.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Inhibrx, Inc.10% owner · 1 transaction | — | 1.16Mas of May 2024 | — | — | — |
| Kayyem Jon FaizDirector · 22 transactions | — | 1.06Mas of Mar 2025 | 818.6K | 451.5K | — |
| Lappe MarkChief Executive Officer, Director · 14 transactions | — | 1.05Mas of Sep 2024 | 761.4K | 164.0K | — |
| Eckelman Brendan P.Chief Scientific Officer · 3 transactions | — | 473.9Kas of May 2024 | 513.9K | — | — |
| Forsyth DouglasDirector · 3 transactions | — | 224.6Kas of Aug 2024 | 149.6K | 75.0K | — |
| Halvorsen Ole Andreas +7 co-filers10% owner · 3 transactions | — | 102.9K | — | — | 350.0K |
| Vuori Kristiina MDDirector · 4 transactions | — | 20.4Kas of Oct 2024 | — | 20.4K | — |
| Manhard KimberlyDirector · 1 transaction | — | 10.0Kas of Aug 2024 | — | 10.0K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +371.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.